Results released Friday show itepekimab succeeded in one Phase 3 trial but failed in a second, sinking shares of both partner ...

A new NDA was submitted in January 2024, which the FDA did accept, and that was later converted into a priority review. An ...

Peter DeYoung, CEO at Piramal Pharma Limited, explains how Piramal is meeting the growing demand for integrated biologics ...

With a better upfront offer on the table, enough bluebird bio investors have tendered their shares for the company's sale to ...

Teva’s investigational monoclonal antibody, TEV-53408, has been designed for use in adults with celiac disease, for which a ...

In the past, most targeted drug development efforts relied on single biomarkers, but cancer is far more complex. BostonGene’s ...

Such deals allow Chinese firms to profit while minimising capital outlays, but also carry risks, law firm says.

Facing erosion of its mighty Eylea (aflibercept) franchise and near-term loss of exclusivity with Dupixent (dupilumab), Regeneron Pharmaceuticals Inc. took a blow as one of two phase III trials with ...

At the heart of the deal is an anti-Claudin18.2 antibody-drug conjugate being developed for solid tumors, including gastric ...

The National Legal and Policy Center, a right-wing advocacy and watchdog group, had asked the company to revisit its DEI ...

Philadelphia-based biotech Vivodyne has raised $40 million in series A funding to advance its fully robotic, AI-powered ...

KARACHI: With an alarming 97 percent of pharmacies in Pakistan lacking temperature-controlled storage and bio-grade ...